IRIS Accounts Production v23.3.0.418 06452062 Board of Directors 1.7.22 30.6.23 30.6.23 true false true false false true false Ordinary 1.00000 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh064520622022-06-30064520622023-06-30064520622022-07-012023-06-30064520622021-06-30064520622021-07-012022-06-30064520622022-06-3006452062ns10:Originalns15:EnglandWales2022-07-012023-06-3006452062ns14:PoundSterlingns10:Original2022-07-012023-06-3006452062ns10:Originalns10:Director12022-07-012023-06-3006452062ns10:Original2022-07-012023-06-3006452062ns10:Original2023-06-3006452062ns10:Originalns10:PrivateLimitedCompanyLtd2022-07-012023-06-3006452062ns10:Originalns10:SmallEntities2022-07-012023-06-3006452062ns10:Originalns10:AuditExempt-NoAccountantsReport2022-07-012023-06-3006452062ns10:Originalns10:SmallCompaniesRegimeForDirectorsReport2022-07-012023-06-3006452062ns10:SmallCompaniesRegimeForAccountsns10:Original2022-07-012023-06-3006452062ns10:Originalns10:AbridgedAccounts2022-07-012023-06-3006452062ns10:Originalns10:OrdinaryShareClass12022-07-012023-06-3006452062ns10:Originalns10:Director22022-07-012023-06-3006452062ns10:CompanySecretary1ns10:Original2022-07-012023-06-3006452062ns10:Originalns10:RegisteredOffice2022-07-012023-06-3006452062ns10:Original2022-06-3006452062ns10:Originalns5:CurrentFinancialInstruments2023-06-3006452062ns10:Originalns5:CurrentFinancialInstruments2022-06-3006452062ns10:Originalns5:Non-currentFinancialInstruments2023-06-3006452062ns10:Originalns5:Non-currentFinancialInstruments2022-06-3006452062ns5:ShareCapitalns10:Original2023-06-3006452062ns5:ShareCapitalns10:Original2022-06-3006452062ns10:Originalns5:RevaluationReserve2023-06-3006452062ns10:Originalns5:RevaluationReserve2022-06-3006452062ns10:Originalns5:RetainedEarningsAccumulatedLosses2023-06-3006452062ns10:Originalns5:RetainedEarningsAccumulatedLosses2022-06-3006452062ns10:Originalns5:PlantMachinery2022-07-012023-06-3006452062ns10:Originalns5:MotorVehicles2022-07-012023-06-3006452062ns10:Original2021-07-012022-06-3006452062ns10:Original2022-06-3006452062ns10:Originalns10:OrdinaryShareClass12023-06-3006452062ns10:Originalns5:RevaluationReserve2022-06-30
REGISTERED NUMBER: 06452062 (England and Wales)















Unaudited Financial Statements for the Year Ended 30 June 2023

for

Rx Advisor Limited

Rx Advisor Limited (Registered number: 06452062)






Contents of the Financial Statements
for the Year Ended 30 June 2023




Page

Company Information 1

Abridged Balance Sheet 2

Notes to the Financial Statements 4


Rx Advisor Limited

Company Information
for the Year Ended 30 June 2023







DIRECTORS: T Ibrahim
M Ibrahim





SECRETARY: T Ibrahim





REGISTERED OFFICE: 175 Fosse Road South
Leicester
LE3 0FX





REGISTERED NUMBER: 06452062 (England and Wales)





ACCOUNTANTS: Xitax Limited
Pera Business Park
Nottingham Road
Melton Mowbray
Leicestershire
LE13 0PB

Rx Advisor Limited (Registered number: 06452062)

Abridged Balance Sheet
30 June 2023

30.6.23 30.6.22
Notes £    £    £    £   
FIXED ASSETS
Tangible assets 4 148,445 156,638
Investments 5 1,147 1,147
149,592 157,785

CURRENT ASSETS
Debtors 71,905 25,000
Cash at bank 35,079 88,671
106,984 113,671
CREDITORS
Amounts falling due within one year 203,129 223,896
NET CURRENT LIABILITIES (96,145 ) (110,225 )
TOTAL ASSETS LESS CURRENT
LIABILITIES

53,447

47,560

CREDITORS
Amounts falling due after more than one
year

26,668

36,667
NET ASSETS 26,779 10,893

CAPITAL AND RESERVES
Called up share capital 6 2 2
Revaluation reserve 7 145 145
Retained earnings 26,632 10,746
SHAREHOLDERS' FUNDS 26,779 10,893

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 30 June 2023.

The members have not required the company to obtain an audit of its financial statements for the year ended 30 June 2023 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

Rx Advisor Limited (Registered number: 06452062)

Abridged Balance Sheet - continued
30 June 2023


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

All the members have consented to the preparation of an abridged Income Statement and an abridged Balance Sheet for the year ended 30 June 2023 in accordance with Section 444(2A) of the Companies Act 2006.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 4 March 2024 and were signed on its behalf by:





M Ibrahim - Director


Rx Advisor Limited (Registered number: 06452062)

Notes to the Financial Statements
for the Year Ended 30 June 2023

1. STATUTORY INFORMATION

Rx Advisor Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Related party exemption
The company has taken advantage of exemption, under the terms of Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland', not to disclose related party transactions with wholly owned subsidiaries within the group.

Significant judgements and estimates
No significant judgements have had to be made by the directors in preparing these financial statements.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Plant and machinery - 33% on cost
Motor vehicles - 12.5% on cost

Investments in subsidiaries
Investments in subsidiary undertakings are recognised at cost.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Rx Advisor Limited (Registered number: 06452062)

Notes to the Financial Statements - continued
for the Year Ended 30 June 2023

2. ACCOUNTING POLICIES - continued

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 4 (2022 - 4 ) .

4. TANGIBLE FIXED ASSETS
Totals
£   
COST
At 1 July 2022 212,520
Additions 166,003
Disposals (202,966 )
At 30 June 2023 175,557
DEPRECIATION
At 1 July 2022 55,882
Charge for year 23,931
Eliminated on disposal (52,701 )
At 30 June 2023 27,112
NET BOOK VALUE
At 30 June 2023 148,445
At 30 June 2022 156,638

5. FIXED ASSET INVESTMENTS

Information on investments other than loans is as follows:
Totals
£   
COST
At 1 July 2022
and 30 June 2023 2
NET BOOK VALUE
At 30 June 2023 2
At 30 June 2022 2

Investments (neither listed nor unlisted) were as follows:
30.6.23 30.6.22
£    £   
Investment 1,000 1,000
Revaluation 145 145
1,145 1,145

Rx Advisor Limited (Registered number: 06452062)

Notes to the Financial Statements - continued
for the Year Ended 30 June 2023

6. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:
Number: Class: Nominal 30.6.23 30.6.22
value: £    £   
2 Ordinary £1 2 2

7. RESERVES
Revaluation
reserve
£   
At 1 July 2022
and 30 June 2023 145

8. ULTIMATE CONTROLLING PARTY

The ultimate parent undertaking is Bismillah786 Ltd which is a company registered in England and Wales and holds 100% of the issued share capital of the company.